Preferred Label : injections, subcutaneous;
MeSH definition : Forceful administration under the skin of liquid medication, nutrient, or other fluid
through a hollow needle piercing the skin.;
MeSH synonym : subcutaneous injections; injection, subcutaneous; subcutaneous injection;
MeSH annotation : NIM; do not use /util except by MeSH definition; DF: INJECT SUBCUTANEOUS; usually NIM;
Origin ID : D007279;
UMLS CUI : C0021499;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Record concept(s)
See also
See also (suggested by CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Forceful administration under the skin of liquid medication, nutrient, or other fluid
through a hollow needle piercing the skin.
https://www.omedit-centre.fr/medias/Reconstitution-administration_antiinfectieux-injectables.pdf
2024
false
false
false
France
French
guidelines for drug use
drug compounding
injections, intramuscular
anti-bacterial agents
drug stability
injections, subcutaneous
injections, intravenous
drug compounding
Administration of antibiotic (procedure)
Infusion Pumps
infusion pumps, implantable
infusions, parenteral
antibacterials for systemic use
ambulatory care
---
https://www.has-sante.fr/jcms/p_3539072/fr/cosentyx-secukinumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
injections, subcutaneous
biological therapy
secukinumab
chronic disease
---
https://www.has-sante.fr/jcms/p_3539147/fr/nucala-mepolizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
biological therapy
mepolizumab
chronic disease
injections, subcutaneous
---
https://www.has-sante.fr/jcms/p_3539090/fr/remsima-infliximab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
Infliximab
injections, subcutaneous
chronic disease
biological therapy
---
https://www.has-sante.fr/jcms/p_3539093/fr/stelara-ustekinumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
injections, subcutaneous
Ustekinumab
chronic disease
biological therapy
---
https://www.has-sante.fr/jcms/p_3539102/fr/xolair-omalizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
Omalizumab
injections, subcutaneous
biological therapy
chronic disease
---
https://www.has-sante.fr/jcms/p_3539144/fr/kevzara-sarilumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
injections, subcutaneous
sarilumab
biological therapy
---
https://www.has-sante.fr/jcms/p_3539105/fr/enbrel-etanercept-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
-
evaluation of the transparency committee
injections, subcutaneous
biological therapy
Etanercept
chronic disease
---
https://www.has-sante.fr/jcms/p_3539075/fr/orencia-abatacept-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
biological therapy
injections, subcutaneous
Abatacept
chronic disease
---
https://www.has-sante.fr/jcms/p_3539096/fr/kyntheum-brodalumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
biological therapy
chronic disease
brodalumab
injections, subcutaneous
---
https://www.has-sante.fr/jcms/p_3539138/fr/taltz-ixekizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
ixekizumab
biological therapy
injections, subcutaneous
---
https://www.has-sante.fr/jcms/p_3539126/fr/dupixent-dupilumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
biological therapy
dupilumab
injections, subcutaneous
---
https://www.has-sante.fr/jcms/p_3539111/fr/humira-adalimumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
biological therapy
adalimumab
Adalimumab
injections, subcutaneous
---
https://www.has-sante.fr/jcms/p_3539117/fr/fasenra-benralizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
injections, subcutaneous
benralizumab
chronic disease
biological therapy
---
https://www.has-sante.fr/jcms/p_3539141/fr/simponi-golimumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
biological therapy
golimumab
injections, subcutaneous
---
https://www.has-sante.fr/jcms/p_3539084/fr/tremfya-guselkumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
injections, subcutaneous
guselkumab
biological therapy
chronic disease
---
https://www.has-sante.fr/jcms/p_3539114/fr/cimzia-certolizumab-pegol-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
biological therapy
injections, subcutaneous
Certolizumab Pegol
chronic disease
---
https://www.has-sante.fr/jcms/p_3539129/fr/kineret-anakinra-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
anakinra
evaluation of the transparency committee
interleukin 1 receptor antagonist protein
injections, subcutaneous
biological therapy
chronic disease
---
https://www.has-sante.fr/jcms/p_3539132/fr/ilumetri-tildrakizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
biological therapy
injections, subcutaneous
chronic disease
tildrakizumab
---
https://www.has-sante.fr/jcms/p_3539123/fr/tezspire-tezepelumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
injections, subcutaneous
chronic disease
tezepelumab
biological therapy
---
https://www.has-sante.fr/jcms/p_3539081/fr/omvoh-mirikizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
mirikizumab
injections, subcutaneous
biological therapy
---
https://www.has-sante.fr/jcms/p_3539069/fr/ilaris-canakinumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
canakinumab
injections, subcutaneous
chronic disease
biological therapy
---
https://www.has-sante.fr/jcms/p_3539135/fr/roactemra-tocilizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
injections, subcutaneous
biological therapy
tocilizumab
chronic disease
---
https://ansm.sante.fr/tableau-marr/asfotase-alfa
2023
false
false
false
France
French
risk management
guidelines for drug use
asfotase alfa
asfotase alfa
self administration
patients guideline
child
injections, subcutaneous
enzyme replacement therapy
asfotase alfa
hypophosphatasia
---
https://www.has-sante.fr/jcms/p_3390497/fr/sunlenca-lenacapavir-vih
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
Lenacapavir
lenacapavir
anti-hiv agents
HIV-1
drug therapy, combination
hiv infections
drug resistance, multiple, viral
multiresistant HIV-1 infection
administration, oral
injections, subcutaneous
evaluation of the transparency committee
---
https://ansm.sante.fr/tableau-marr/vedolizumab
2022
false
false
false
France
French
pharmacovigilance note
risk management
vedolizumab
infusions, intravenous
injections, subcutaneous
guidelines for drug use
drug monitoring
continuity of patient care
package leaflet
Infections
leukoencephalopathy, progressive multifocal
vedolizumab
antibodies, monoclonal, humanized
---
https://www.cochrane.org/fr/CD008077/PVD_la-vitesse-dinjection-fait-elle-une-difference-dans-limportance-de-la-douleur-et-des-ecchymoses-chez
2021
false
false
false
France
United Kingdom
French
review of literature
injections, subcutaneous
heparin
pain
ecchymosis
injections, subcutaneous
french abstract
time factors
Velocity (distance/time)
comparative study
---
https://www.has-sante.fr/jcms/p_3191666/fr/remsima
2020
false
false
false
France
Infliximab
infliximab
insurance, health, reimbursement
treatment outcome
injections, subcutaneous
drug therapy, combination
methotrexate
arthritis, rheumatoid
adult
guidelines for drug use
antirheumatic agents
evaluation of the transparency committee
---
https://ansm.sante.fr/informations-de-securite/ceftriaxone-rocephine-r-et-generiques-rappel-sur-les-voies-dadministration
2019
false
false
false
France
French
guidelines for drug use
ceftriaxone
anti-bacterial agents
ceftriaxone
injections, subcutaneous
-
-
-
-
---
https://www.has-sante.fr/portail/jcms/c_2847899/fr/decapeptyl-lp
2018
false
false
false
false
France
French
evaluation of the transparency committee
injections, subcutaneous
triptorelin
prostate cancer
antineoplastic agents, hormonal
triptorelin pamoate
prostatic neoplasms
---
http://www.cochrane.org/fr/CD009136
2013
United Kingdom
France
French
anticoagulotherapy
review of literature
french abstract
heparin
pregnancy
injections, subcutaneous
anticoagulants
pregnancy complications, hematologic
---
http://www.has-sante.fr/portail/display.jsp?id=c_614428
http://www.has-sante.fr/portail/jcms/c_1367956/en/priorix
http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-03/priorix_ri_avis1_ct12189.pdf
2013
France
French
injections, subcutaneous
measles-mumps-rubella vaccine
vaccination
measles
mumps
rubella
vaccines, attenuated
insurance, health, reimbursement
mumps virus
measles virus
rubella virus
infant
child
immunization schedule
morbilli, combinations with parotitis and rubella, live attenuated
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/display.jsp?id=c_574472
http://www.has-sante.fr/portail/jcms/c_1543507/fr/imiject
2013
France
French
injections, subcutaneous
sumatriptan
pharmaceutical solutions
cluster headache
insurance, health, reimbursement
sumatriptan
serotonin 5-HT1 receptor agonists
sumatriptan succinate
evaluation of the transparency committee
---
http://www.cochrane.org/fr/CD009107
2012
United Kingdom
France
French
meta-analysis
pain management
labor pain
treatment outcome
water
injections, intradermal
injections, subcutaneous
analgesia, obstetrical
back pain
french abstract
---
http://www.has-sante.fr/portail/display.jsp?id=c_619527
2007
France
French
anticoagulants
injections, subcutaneous
fibrinolytic agents
insurance, health, reimbursement
polysaccharides
venous thromboembolism
postoperative complications
clinical trials as topic
treatment outcome
renal insufficiency
fondaparinux
fondaparinux sodium
polysaccharides
evaluation of the transparency committee
Fondaparinux
---
http://www.has-sante.fr/portail/display.jsp?id=c_538427
2007
France
French
anticoagulants
injections, subcutaneous
fibrinolytic agents
pharmaceutical solutions
polysaccharides
venous thromboembolism
abdominal neoplasms
treatment outcome
postoperative complications
abdomen
insurance, health, reimbursement
fondaparinux
fondaparinux sodium
polysaccharides
evaluation of the transparency committee
Fondaparinux
---
http://www.has-sante.fr/portail/display.jsp?id=c_400615
2005
France
French
polysaccharides
anticoagulants
injections, subcutaneous
fibrinolytic agents
insurance, health, reimbursement
venous thrombosis
acute disease
pulmonary embolism
adult
aged
treatment outcome
clinical trials, phase iii as topic
polysaccharides
anticoagulants
fibrinolytic agents
fondaparinux
fondaparinux sodium
fondaparinux sodium
evaluation of the transparency committee
Fondaparinux
Fondaparinux
---
http://www.has-sante.fr/portail/display.jsp?id=c_400001
2004
France
French
Factor Xa Inhibitors
anticoagulants
injections, subcutaneous
fibrinolytic agents
insurance, health, reimbursement
polysaccharides
renal insufficiency
hip fractures
postoperative complications
factor xa
venous thromboembolism
orthopedic procedures
time
treatment outcome
fondaparinux
fondaparinux sodium
evaluation of the transparency committee
Fondaparinux
---
https://www.cadth.ca/sites/default/files/pdf/271_No29_insulin_preassess_e.pdf
https://www.cadth.ca/sites/default/files/pdf/271_No29_insulin_preassess_f.pdf
2004
Canada
English
hypoglycemic agents
insulin
injections, subcutaneous
Evidence-Based medicine
canada
treatment outcome
bibliography of medicine
insulin infusion systems
child
adult
insulin (human)
health technology assessment
drug evaluation
comparative study
---
http://www.has-sante.fr/portail/display.jsp?id=c_399650
2002
France
French
injections, subcutaneous
measles virus
measles-mumps-rubella vaccine
vaccination
vaccines, attenuated
rubella virus
mumps virus
mumps
rubella
measles
insurance, health, reimbursement
infant
child
adolescent
adult
morbilli, combinations with parotitis and rubella, live attenuated
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/display.jsp?id=c_399496
2002
France
French
fibrinolytic agents
injections, subcutaneous
pharmaceutical solutions
nadroparin
anticoagulants
insurance, health, reimbursement
adult
venous thromboembolism
postoperative complications
venous thrombosis
renal dialysis
myocardial infarction
angina, unstable
nadroparin
anticoagulants
fibrinolytic agents
product surveillance, postmarketing
time
nadroparin
evaluation of the transparency committee
---